File Download

There are no files associated with this item.

Supplementary

Conference Paper: Effect of empagliflozin on liver fat in metabolic-dysfunction associated steatotic liver disease patients without diabetes mellitus: a randomized, double-blind, placebo-controlled trial

TitleEffect of empagliflozin on liver fat in metabolic-dysfunction associated steatotic liver disease patients without diabetes mellitus: a randomized, double-blind, placebo-controlled trial
Authors
Cheung, KSNg, HYHui, RWHLam, LKMak, LYHo, YCTan, JTChan, EWSeto, WK
Issue Date18-May-2024
Persistent Identifierhttp://hdl.handle.net/10722/339933

 

DC FieldValueLanguage
dc.contributor.authorCheung, KS-
dc.contributor.authorNg, HY-
dc.contributor.authorHui, RWH-
dc.contributor.authorLam, LK-
dc.contributor.authorMak, LY-
dc.contributor.authorHo, YC-
dc.contributor.authorTan, JT-
dc.contributor.authorChan, EW-
dc.contributor.authorSeto, WK-
dc.date.accessioned2024-03-11T10:40:25Z-
dc.date.available2024-03-11T10:40:25Z-
dc.date.issued2024-05-18-
dc.identifier.urihttp://hdl.handle.net/10722/339933-
dc.languageeng-
dc.relation.ispartofDigestive Disease Week 2024 (18/05/2024-21/05/2024, , , Washington, DC, USA)-
dc.titleEffect of empagliflozin on liver fat in metabolic-dysfunction associated steatotic liver disease patients without diabetes mellitus: a randomized, double-blind, placebo-controlled trial-
dc.typeConference_Paper-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats